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INTRODUCTION 
IgE-mediated allergies are extremely common in adults
and children with asthma. An allergen-based treatment is
therefore of great importance for the management of allergic
asthma (1). Specific immunotherapy is thought to be the only
treatment that may alter the natural course of allergic disease
(2). However, it has been reported that immunotherapy for
asthma does not provide benefits beyond those achievable
with alternative remedies (3).
Some people are sensitized to only one class of allergens
(monosensitization), whereas others are sensitized to more
than one class of allergens (polysensitization) (4, 5). Why in-
dividuals become sensitized to one or more classes of allergens
is not well understood, although a number of genetic and
environmental factors have been implicated (6). Recently
there has been an increase in antigen sensitivity, and the num-
ber of asthma patients who have become sensitive to several
antigens is also increasing (7). In addition, polysensitization
has been reported to be associated with a lower health-relat-
ed quality of life in intermittent asthma patients (8). Further-
more, there has also been a suggestion that the specific and
total serum IgE levels in multi-antigen-sensitive patients are
high, and immunotherapy is not as effective in these patients
as in those who are sensitive to a single antigen. However,
serum specific IgG levels have been reported to be significantly
increased after immunotherapy in both types of patients (8).
The present study was undertaken to compare allergic in-
dices and the efficacy of immunotherapy in patients with typ-
ical allergic asthma who are sensitive to one or more antigens.
MATERIALS AND METHODS 
Subjects 
Among patients who were diagnosed with asthma at the
pediatric allergy clinic at Severance hospital, 130 patients
who underwent specific immunotherapy for more than 18
months were included in this study.
Asthma was defined as recurrent wheezing or cough, in the
absence of a cold, in the preceding 12 months, with a physi-
cian’s diagnosis (at any time in the patient’s history), of bron-
chial hyperresponsiveness upon methacholine challenge (PC20
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Comparison of Allergic Indices in Monosensitized and Polysensitized
Patients with Childhood Asthma
Monosensitization differs both immunologically and clinically from polysensitization,
and specific immunotherapy is more effective in patients sensitized only to a single
pollen than in multiple-pollen sensitized patients. To further examine the differences
between monosensitized and polysensitized allergies, allergic indices were exam-
ined in 68 monosensitized and 62 polysensitized patients with childhood asthma.
Measurements included symptom scores, eosinophil counts, skin prick tests, serum
total and specific IgE levels, and IL-10 levels, and were used to compare allergic
indices between the two groups. Patients were followed for 18 months following
immunotherapy to examine the effectiveness of the treatment. Symptom scores
and total IgE levels were significantly higher in the polysensitized group than those
in the monosensitized group (p<0.05). The levels of skin test response decreased
significantly in both groups following immunotherapy. In the monosensitized group,
symptom scores and specific IgE levels were significantly reduced after immunother-
apy (p<0.05). In the polysensitized group, symptom scores were reduced after im-
munotherapy (p<0.05), but the degree of reduction was less than that of the mono-
sensitized group (p<0.05). Moreover, in the polysensitized group, specific IgE levels
after immunotherapy did not differ from that before immunotherapy. Serum IL-10
levels were not significantly increased after immunotherapy in either group. In con-
clusion, polysensitized patients tend to show higher allergic indices and immunother-
apy might be less effective for these patients.
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≤16 mg/mL) and at least 12% reversibility of FEV1 after
inhalation of 2 agonist, per criteria of the American Tho-
racic Society (ATS) (10-12).
Subjects sensitized to only the house dust mite class of aller-
gens were defined as monosensitized, and those sensitized to
two to more classes of allergens, including house dust mites,
were defined as polysensitized. Because it was considered that
atopic subjects are frequently sensitized to more than one
allergen belonging to clusters of allergen classes (13, 14).
In order to compare allergic indices between the two groups,
symptom scores, total serum IgE levels, specific IgE levels,
eosinophil counts, IL-10 levels, and allergic skin test response
levels were examined before and after immunotherapy. In-
formed, written consent was obtained from all participants
before inclusion in the study, which was previously approved
by the Severance Hospital Institutional Review Board.
Allergic skin prick tests 
Skin prick tests were performed with 32 allergens includ-
ing: i) house dust mites (house dust, Dermatophagoides ptero-
nyssinus, D. farinae), ii) animal dander (cat hair and dander,
dog hair, rabbit hair), iii) pollens (sagebrush, ragweed, oak,
birch, etc.), iv) molds (Aspergillus, Alternaria, etc.), and v)
cockroach (American cockroach, German cockroach) (Torii &
Co., Tokyo, Japan), together with negative (saline) and posi-
tive (0.5% histamine HCl) controls. Wheal size was measured
after 15 min (15). A positive reaction was defined as a wheal
larger than 3 mm (16).
The degree of skin test response was expressed as a ratio
obtained by dividing the wheal size from house dust mite
(D. farinae) by that from the positive control.
Spirometry and methacholine challenge test
Lung function was measured by spirometry (Vmax encore;
VIASYS Healthcare Inc., Conshohocken, U.S.A.) performed
according to American Thoracic Society standards with the
children standing. Bronchial hyperresponsiveness was assessed
in all subjects by the methacholine challenge test. Children
were eligible if they could perform reproducible spirometry
and had an FEV1 of at least 70% of the predicted value (17).
The concentration of methacholine causing a 20% decrease
in FEV1 (PC20) was determined, and a challenge was consid-
ered positive if the PC20 was 16 mg/mL or less. Anti-inflam-
matory preparations and bronchodilators were withheld for
24 hr before the testing.
Symptom scores
Symptoms such as dyspnea, wheezing, and cough, which
indicate asthma, were scored as 0-2, respectively, through
interview with the subjects and their parents (18).
Measurement of blood eosinophils, serum total IgE, 
specific IgE and IL-10 levels
After peripheral blood samples were obtained from the sub-
jects, the total IgE levels and levels of IgE against house dust
mites (D. farinae) were measured using the CAP system FEIA
(Pharmacia & Upjohn Diagnostic AB, Uppsala, Sweden). The
NE-8000 system (Sysmax, Japan) was used to automatically
count eosinophils in peripheral blood. Serum IL-10 levels
were measured according to the sandwich ELISA method.
The minimum detectable dose of human IL-10 is typically
less than 0.5 pg/mL (R & D systems Inc., Minneapolis, Min-
nesota, U.S.A.). 
Immunotherapy 
The first stage of treatment included administration of
minimal doses of vaccines, after which the dose was increased
weekly until reaching the maximum dose that the patient
could tolerate. The second stage of immunotherapy was the
maintenance stage, in which the maximum dose of antigen
was maintained monthly for up to 18 months (19). Monosen-
sitized subjects received immunotherapy with house dust mite
vaccines and polysensitized subjects with mixed vaccines de-
pending on the sensitivity of the subjects. Both groups had
the same dosage of house dust mite antigen in the vaccines.
Statistical analysis 
All values are expressed as average±SD. Using the SPSS
11.0 statistical package program, statistical difference was
determined between the two groups according to paired t-
tests. p values less than 0.05 were considered to be significant.
RESULTS 
Comparison of clinical characteristics and allergy indices
between monosensitized and polysensitized groups
Among 130 total subjects, 68 patients belonged to the
monosensitized group and 62 patients to the polysensitized
group. The average ages of patients in the two groups were
6.3±0.3 yr and 7.6±0.3 yr, respectively. The male to female
ratio was 1:1 in the monosensitized group and 2.1:1 in the
polysensitized group. Allergic diseases other than asthma
were found in 58 subjects in the monosensitized group (85%)
and 57 subjects in the polysensitized group (92%). The most
frequently accompanying allergic disease other than asthma
was allergic rhinitis, followed by allergic conjunctivitis and
atopic dermatitis, and no significant difference existed bet-
ween the two groups with regard to the presence of these aller-
gic diseases. The average number of positive antigens accord-
ing to the allergic skin test was 5.0±0.5 in the polysensitized
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group, and the most frequently seen antigen was the house
dust mite, followed by Alternaria and cockroach. The symp-
tom scores of polysensitized subjects were significantly higher
than those of monosensitized subjects (p<0.05). The level of
IgE specific to house dust mites was increased in the polysen-
sitized group, but this increase was not statistically significant
(Table 1). The total serum IgE levels in the polysensitized
group were significantly increased compared with that of
the monosensitized group, both before and after immunother-
apy (p<0.05). The eosinophil counts were also high in the poly-
sensitized group compared with the monosensitized group;
however, this difference was also not significant (Table 2).
Efficacy of immunotherapy 
The results of tests conducted before and after immunother-
apy showed that changes in the total serum IgE levels, eosi-
nophil counts and serum IL-10 levels were not statistically
different between the monosensitized group and polysensi-
tized group (Table 2). In the monosensitized group, symp-
tom scores were decreased from 5.0±0.1 before immunother-
apy to 1.7±0.1 after immunotherapy (p<0.05) (Fig. 1). The
levels of house dust mite-specific IgE were decreased signif-
icantly from 97.3±34.2 IU/mL before immunotherapy to
59.2±21.9 IU/mL after immunotherapy (p<0.05) (Fig. 2).
The levels of skin test response were also decreased signifi-
cantly after immunotherapy (p<0.05) (Table 2). In the poly-
sensitized group, symptom scores were decreased from 5.3
±0.1 before immunotherapy to 2.4±0.1 after immunother-





Number of subjects 68 62
Age (yr)* 6.3±0.3 7.6±0.3
Sex (male:female) 1:1 2.1:1
Number with other diseases (%) 58 (85) 57 (92)
Number of sensitized antigens* 1 5.0±0.5
Symptom score*,� 5.0±0.1 5.3±0.1
Specific IgE of house dust mite 101.8±24.0 129.9±25.4
(IU/mL)*
Table 1. Comparison of clinical characteristics and allergy in-
dices between monosensitized and polysensitized groups
Data are expressed as mean±SD.
*A/H ratio of wheal of allergen and histamine; �p<0.05, compared to the level of skin test before immunotherapy; �p<0.05, compared to total IgE level
of polysensitized group before immunotherapy; �p<0.05, compared to total IgE level of polysensitized group after immunotherapy.
Monosensitized group
Before immunotherapy After immunotherapy
Polysensitized group
Before immunotherapy After immunotherapy
Total IgE level (IU/mL) 397.7±62.2� 450.0±71.6� 661.1±89.9 622.5±83.9
Eosinophil count (/ L) 499.2±103.7 359.7±28.6 557.5±54.5 526.3±59.4
Skin test response* 1.8±0.1 1.2±0.1� 1.7±0.1 1.3±0.1�
IL-10 (pg/mL) 15.4±9.1 30.1±19.1 4.1±1.4 5.1±2.8







Fig. 1. Symptom scores differ significantly between monosensi-
tized and polysensitized groups. Symptom scores also decrease
significantly after immunotherapy in both groups. Error bars rep-























Fig. 2. The level of IgE specific to house dust mite (D. farinae) dec-
reases significantly after immunotherapy in the monosensitized
group (p<0.05), but not in the polysensitized group. Error bars
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(p<0.05). The levels of house dust mite-specific IgE actually
increased from 65.8±21.6 IU/mL before immunotherapy
to 73.2±40.2 IU/mL after immunotherapy (Fig. 2). How-
ever, the degree of skin test response was decreased signifi-
cantly after immunotherapy (p<0.05) (Table 2).
DISCUSSION 
The results from this study showed differences in allergic
indices between monosensitized and polysensitized groups.
The symptom scores and levels of total IgE were higher in
the polysensitized group compared with the monosensitized
group. The specific IgE levels and eosinophil counts were
high in the polysensitized group; however, these increases
were not significant, in concordance with the previous stud-
ies in which the total and specific IgE levels were higher in
polysensitized groups (9, 20). 
Pene et al. (20) reported that the reason for different IgE
immune response between monosensitized and polysensitized
groups lies in the difference in IL-4 secretion. Therefore, the
subjects could be divided into high IgE responders and low
IgE responders. Based on these studies, we could consider
two genetic mechanisms involved in controlling the allergic
response. In the case of the monosensitized group (low IgE
responders), allergy sensitization has a close relationship with
the HLA-DR or DP molecule, whereas patients in the poly-
sensitized group (high IgE responders) showed allergy sensi-
tization regardless of HLA-DR or DP, suggesting that epi-
topes binding with MHC were degenerated (21, 22).
Although there still exists controversy over the value of
immunotherapy, studies on its efficacy have been continued
(3, 23). In the present study, we found that the symptom scores
and the levels of skin test response were decreased after immu-
notherapy, however, the total IgE levels and eosinophil counts
showed no statistically significant changes. Koker et al. (24)
reported that total IgE levels and eosinophil counts were dec-
reased after immunotherapy, however, Jarolim et al. (25) report-
ed increase of IgG1, IgG4 and total IgE levels, and Turner et
al. (26) and McHugh et al. (27) reported no change in spe-
cific IgE levels after immunotherapy. Bousquet et al. (8) stat-
ed that the efficacy of immunotherapy is expressed differently
between the monosensitized group and the polysensitized
group, and that the efficacy of immunotherapy was decreased
in the polysensitized group when symptom scores, PGD2,
skin test response levels, and specific IgG levels were evalu-
ated. In the present study, the symptom scores and the spe-
cific IgE levels were significantly decreased in the monosen-
sitized group, compared with the polysensitized group, indi-
cating a difference in the efficacy of immunotherapy. As des-
cribed earlier, this decreased efficacy in immunotherapy in
the polysensitized group was likely due to an increased IgE
response against antigens in the polysensitized group so that
these subjects probably did not respond to the immunother-
apy, which was composed of optimal allergen doses required
in the monosensitized group. Furthermore, antigen mixtures
used in the polysensitized group were shown to be unstable
compared with the single antigen solutions in a study using
an antigen mixture composed of house dust mite, cat hair,
or ragweed (28). One limitation in our study may be that we
did not evaluate the efficacy of immunotherapy between the
groups according to the severity of asthma. It is postulated
that the efficacy of immunotherapy may be influenced by the
severity of asthma, and thus it may have been better for future
reference if the efficacy was evaluated independently in patient
groups subdivided according to the level of severity of the
asthma. However, it should be noted that in our study, there
was a significant difference in the degree of improvement in
symptom scores and specific IgE levels between our two
groups, but not in the scores or levels themselves.
Human IL-10 inhibits the secretion of IFN- and IL-2
from Th1 cells, affects Th2 cells to inhibit the secretion of
IL-4 and IL-5, and inhibits the secretion of IL-6 and TNF-
from mononuclear phagocytes (29). Therefore, it is thought
that IL-10 functions as an anti-inflammatory cytokine in the
body by inhibiting the secretion of IgE and the proliferation
and activation of eosinophils to decrease allergic inflamma-
tion responses. It is also thought to inhibit the non-specific
cellular inflammation responses of mononuclear phagocytes
and Th1 cells (30). Borish et al. (30) reported a relatively dec-
reased ability to secrete IL-10 in bronchoalveolar lavage in
asthma patients, and Hobbs et al. (31) reported dysfunction
in the transcription of the IL-10 gene in allergy patients. In
the present study, although not statistically significant, we
found an increased level of IL-10 in monosensitized patients,
and believe that the IL-10 levels were increased following
immunotherapy. These results may indicate that IL-10 func-
tion, which might affect allergic asthma, was recovered thro-
ugh immunotherapy.
In conclusion, monosensitized groups and polysensitized
groups are immunologically different, and these differences
are most likely controlled by the secretion pattern of various
cytokines, as allergic indices are more severe and immunother-
apy might be less effective in the polysensitized group. Based
on these conclusions, to optimize the treatment course of the
polysensitized patients, further study will be necessary and
the efficacy of immunotherapy in this group requires further
evaluation as well.
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